DPYSL3 and prostate cancer: Analysis of one dataset from publically available OncomineTM database [26] revealed that DPYSL3 expression was largely reduced in metastatic prostate cancer tissues compared to benign prostatic tissues (about 20-fold) and primary prostate cancers (about 15-fold) (Figure 1A).